Related Experiment Video
Updated: Jun 1, 2026
10:04
Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells
Published on: August 1, 2025
Dramatic improvement of DC-based immunotherapy against various malignancies
Yui Harada1, Yoshikazu Yonemitsu
1R and D Laboratory for Innovative Biotherapeutics, Kyushu University Graduate School of Pharmaceutical Sciences, Fukuoka 812-8582, Japan.
Frontiers in Bioscience (Landmark Edition)
|May 31, 2011
Summary
This study introduces a novel cytokine-based method to significantly increase functional dendritic cells (DCs) for cancer immunotherapy. DCs activated by a specific virus showed superior anti-cancer effects compared to current vaccines.
Area of Science:
- Immunology
- Cancer Research
- Cell Biology
Background:
- Dendritic cells (DCs) are vital for immune regulation.
- Current DC-based cancer immunotherapy often shows limited clinical efficacy.
- Insufficient DC numbers and suboptimal activation contribute to low treatment success.
Purpose of the Study:
- To investigate the impact of DC numbers and activation methods on anti-cancer immunotherapy.
- To develop an improved method for generating functional DCs for cancer treatment.
- To evaluate the efficacy of rSeV-activated DCs in preclinical models.
Main Methods:
- Established a simple cytokine-based culture method for large-scale production of functional murine and human DCs.
- Activated DCs using a replication-deficient recombinant Sendai virus (rSeV).
- Compared the efficacy of rSeV-activated DC vaccines with current DC vaccines in preclinical models of malignancy.
Main Results:
- Successfully generated log-scale numbers of functional DCs using the novel cytokine-based method.
- Demonstrated that rSeV-activated DCs exhibit significantly enhanced anti-tumor effects compared to current DC vaccines.
- Confirmed that both the quantity and activation method of DCs are critical for their anti-tumor efficacy.
Conclusions:
- The developed cytokine-based culture method offers a breakthrough for producing large numbers of functional DCs.
- rSeV-activated DCs represent a promising and more effective strategy for cancer immunotherapy.
- This approach has the potential to overcome current limitations and improve malignancy treatment outcomes.
Related Concept Videos
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
01:30Cancer Vaccines
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...